Inside the research

Repligen Corporation

RGEN Research profile · latest available data

Price overview

$189.68

▼ -0.97 (-0.5%)

52w hi$190.65
52w lo$102.87
Vol1.50M
As of25 Sep 2026

The Verdict

Hold

Our score -0.15

Short-0.18
Medium+0.06
Long-0.50

computed 2026-09-27

Key fundamentals

Repligen Corporation

Healthcare · Medical Instruments & Supplies

Market cap$10.70B
Enterprise value$10.59B
Trailing P/E263.44x
Forward P/E71.58x
EV / EBITDA73.46x
P / S (ttm)13.63x
Profit margin5.3%
Return on equity2.0%
Revenue growth+11.9%
Earnings growth-65.9%
Debt / equity32.72

Layer Breakdown

LayerRawContribution
Fundamental-0.11
Sector+0.08
Technical+0.26
Earnings+0.00
Sentiment-0.68

macro × 1.00 · 2026-09-27

Business overview

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

United States · www.repligen.com

Risk Metrics

Beta vs SPX1.41
Corr SPX0.46
Annual vol49.0%
Annual ret+26.1%
Sharpe0.53
Max DD-41.0%

Window: 504 trading days (504 obs)

Material Events

DateEvent8-K
2026-07-28Earnings Release, Exhibitsread
2026-07-22Material Agreement, Earnings Release…read
2026-05-15Shareholder Voteread
2026-05-05Earnings Release, Exhibitsread
2026-02-24Earnings Release, Exhibitsread
2026-01-06Officer / Director Change, Reg FD Disclosure…read
2025-10-28Earnings Release, Exhibitsread
2025-09-02Officer / Director Change, Exhibitsread
2025-07-29Earnings Release, Exhibitsread
2025-05-15Bylaws Amendment, Shareholder Vote…read
2025-04-29Earnings Release, Exhibitsread
2025-02-20Earnings Release, Exhibitsread

Flow & Concentration

Insider 180d net$0
Insider buys / sells0 / 0
Insider biasNeutral
13F holders7
Top-5 share99.3%
HHI4,050 (concentrated)

Top Holders

HolderValueShares
Capital Research / Capital World$108.47M795.01K
Citadel Advisors$58.27M427.11K
State Street Corp$15.32M14.95M
Fidelity / FMR LLC$8.29M8.11M
Millennium Management$3.68M27.00K
AQR Capital Management$1.21M8.94K
T. Rowe Price Group$239.08K1.75M

As of 2026-06-30

SEC Filings

DateFormDoc
2026-07-2910-Qview
2026-07-288-Kview
2026-07-228-Kview
2026-07-174view
2026-06-264view
2026-05-184view
2026-05-184view
2026-05-184view
2026-05-184view
2026-05-184view
2026-05-184view
2026-05-184view
2026-05-184view
2026-05-158-Kview
2026-05-084view

The Long Run

FY 2011–2025 · 15 years

LineLatestCAGRTrend
Revenue$32.45M+7.2%
Gross profit$39.98M+55.2%
Operating income$47.70M+33.0%
Net income$35.60M+29.7%
Cash from ops$113.92M+51.5%

Indices

S&P MidCap 400

Recent Sessions

DateOpenHighLowCloseVol
Sep 25$189.92$191.51$186.91$189.681.50M
Sep 24$184.10$192.49$183.75$190.651.60M
Sep 23$186.38$188.95$181.71$184.53934.80K
Sep 22$180.72$188.20$180.00$186.751.16M
Sep 21$176.89$182.25$176.22$180.71857.60K

Understand the score. Research layers are inputs to a model, and the available data has limits.

Read the methodology →